依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床观察

发布时间：2018-02-04 00:36

本文关键词： 依达拉奉丁苯酞急性缺血性脑卒中炎性因子血清微小RNA 神经功能　出处：《中国药房》2016年29期 　论文类型：期刊论文

【摘要】：目的:观察依达拉奉联合丁苯酞治疗急性缺血性脑卒中(AIS)的临床疗效及安全性。方法:选取AIS患者258例,按随机数字表法分为观察组和对照组,各129例。两组患者均给予抗血小板聚集、改善微循环、控制血压、降糖、调脂、稳定斑块和营养脑细胞等常规治疗。对照组患者在常规治疗基础上口服丁苯酞胶囊200 mg,tid;观察组患者在对照组基础上给予依达拉奉注射液30 mg加入氯化钠注射液100 ml中,ivgtt,bid。两组患者均持续治疗14 d。观察两组患者治疗前及治疗后7、14 d血清炎性因子、血清微小RNA(mi R)222及神经功能缺损评分,并比较两组患者临床疗效及不良反应发生情况。结果:治疗前,两组患者血清炎性因子、mi R-222及神经功能缺损评分比较,差异均无统计学意义(P0.05);治疗后7、14 d,两组患者血清炎性因子水平及神经功能缺损程度评分均显著降低,血清mi R-222显著升高,且观察组明显优于对照组,差异均有统计学意义(P0.05)。观察组患者临床总有效率为92.2%,显著高于对照组的69.8%,差异有统计学意义(P0.05)。两组患者均未见明显不良反应发生。结论:依达拉奉联合丁苯酞治疗AIS疗效显著,能明显降低患者血清炎性因子水平,促进mi R-222表达,改善神经功能,且安全性较好。
[Abstract]:Objective: to observe the efficacy and safety of Edaravone combined with butyphthalide in the treatment of acute ischemic stroke. Methods: 258 patients with AIS were selected. According to the random number table method, the patients were divided into observation group (n = 129) and control group (n = 129). The patients in both groups were given anti-platelet aggregation, improving microcirculation, controlling blood pressure, lowering blood sugar and regulating lipid. The patients in the control group were treated with butyphthalide capsule 200 mg tid on the basis of routine therapy. The patients in the observation group were given 30 mg Edaravone injection in 100ml sodium chloride injection on the basis of the control group. The patients in both groups were treated continuously for 14 days. The serum inflammatory factors, serum RNA(mi RN 222 and neurological impairment score were observed before and 7 days after treatment in both groups. Results: before treatment, the patients in the two groups were compared with the scores of serum inflammatory factor mi-222 and neurological impairment score. The difference was not statistically significant (P 0.05). On the 7th and 14th day after treatment, the levels of serum inflammatory factors and the neurological impairment score in both groups were significantly decreased, and the serum mi-222 was significantly increased, and the observation group was significantly better than the control group. The difference was statistically significant (P 0.05). The total effective rate of the observation group was 92.22%, which was significantly higher than that of the control group (69.8%%). The difference was statistically significant (P 0.05). There were no significant adverse reactions in both groups. Conclusion: Edaravone combined with butyphthalide can significantly reduce the level of serum inflammatory factors in patients with AIS. Promote the expression of mi-222, improve neural function, and the safety is good.
【作者单位】：哈尔滨医科大学附属第一医院神经内科;哈尔滨医科大学附属第一医院药学部;
【分类号】：R743.3
【正文快照】： 急性缺血性脑卒中(AIS)是由多种因素引发的脑血液循环障碍,细胞内钙调蛋白(Ca M)表达量升高引发的钙超载是导致AIS损伤的主要原因,其中调控基因在转录后表达的非翻译小分子微小RNA(mi R)222可与Ca M基因靶向结合,在AIS的发生发展中扮演着重要角色[1]。因此,有效调控血清mi R-2

【相似文献】